After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

The Danish pharma is trying to stay ahead of arch rivals Eli Lilly and Sanofi in an ... available to NHS patients in the UK. Lilly is developing Tempo Smart Button, a device that attaches to ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Conditions are getting a bit more challenging for the drugmaker.

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes. Much of the ...

MangoRx said it “strongly refutes” claims made by Eli Lilly that it improperly copied blockbuster weight-loss medicines for sale on its telemedicine platform. MangoRx was responding to Eli ...